Advanced search
Publication Cover
Pharmacogenomics Volume 12, 2011 - Issue 7
Submit an article Journal homepage
291
Views
0
CrossRef citations to date
0
Altmetric
Review

Pharmacogenetics of Leptin in Antipsychotic-Associated Weight Gain and Obesity-Related Complications

Amy K Lee1 University of Illinois at Chicago College of Pharmacy, Department of Pharmacy Practice, 833 S. Wood St, Rm 164 (M/C 886), Chicago, IL 60612, USAView further author information
&
Jeffrey R Bishop1 University of Illinois at Chicago College of Pharmacy, Department of Pharmacy Practice, 833 S. Wood St, Rm 164 (M/C 886), Chicago, IL 60612, USA;2 Tel.:+1 312 413 3495 Fax: +1 312 996 [email protected]View further author information
Pages 999-1016 | Published online: 25 Jul 2011

Bibliography

  • Allison DB , MentoreJL, HeoM et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156(11) , 1686–1696 (1999).
  • American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care27(2) , 596–601 (2004).
  • Parsons B , AllisonDB, LoebelA et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr. Res. 110(1–3) , 103–110 (2009).
  • Arranz MJ , De Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry12(8) , 707–747 (2007).
  • de Luca V , MuellerDJ, de Bartolomeis A, Kennedy JL. Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int. J. Neuropsychopharmacol.10(5) , 697–704 (2007).
  • Sicard MN , ZaiCC, TiwariAK et al. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics 11(11) , 1561–1571 (2010).
  • Flegal KM , CarrollMD, OgdenCL, CurtinLR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA303(3) , 235–241 (2010).
  • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation106(25) , 3143–3421 (2002).
  • Mottillo S , FilionKB, GenestJ et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J. Am. Coll. Cardiol. 56(14) , 1113–1132 (2010).
  • Citrome L , BlondeL, DamatarcaC. Metabolic issues in patients with severe mental illness. South Med. J.98(7) , 714–720 (2005).
  • Holt RI , PevelerRC. Obesity, serious mental illness and antipsychotic drugs. Diabetes. Obes. Metab.11(7) , 665–679 (2009).
  • Newcomer JW . Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J. Clin. Psychiatry68(Suppl. 1) , 20–27 (2007).
  • Brown S , BirtwistleJ, RoeL, ThompsonC. The unhealthy lifestyle of people with schizophrenia. Psychol. Med.29(3) , 697–701 (1999).
  • Jin H , MeyerJM, MudaliarS, JesteDV. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr. Res.100(1–3) , 70–85 (2008).
  • Kinon BJ , BassonBR, GilmoreJA, TollefsonGD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J. Clin. Psychiatry62(2) , 92–100 (2001).
  • Gentile S . Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications. Obes. Rev.10(5) , 527–542 (2009).
  • Leucht S , CorvesC, ArbterD, EngelRR, LiC, DavisJM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet373(9657) , 31–41 (2009).
  • Leucht S , KomossaK, Rummel-KlugeC et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatry 166(2) , 152–163 (2009).
  • Lieberman JA , StroupTS, McevoyJP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12) , 1209–1223 (2005).
  • Gebhardt S , HaberhausenM, Heinzel-GutenbrunnerM et al. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J. Psychiatr. Res. 43(6) , 620–626 (2009).
  • Aichhorn W , WhitworthAB, WeissEM, MarksteinerJ. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Saf.29(7) , 587–598 (2006).
  • Basson BR , KinonBJ, TaylorCC, SzymanskiKA, GilmoreJA, TollefsonGD. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J. Clin. Psychiatry62(4) , 231–238 (2001).
  • Kinon BJ , KaiserCJ, AhmedS, RotelliMD, Kollack-WalkerS. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J. Clin. Psychopharmacol.25(3) , 255–258 (2005).
  • Safer DJ . A comparison of risperidone-induced weight gain across the age span. J. Clin. Psychopharmacol.24(4) , 429–436 (2004).
  • Strassnig M , MiewaldJ, KeshavanM, GanguliR. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr. Res.93(1–3) , 90–98 (2007).
  • Saddichha S , AmeenS, AkhtarS. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. J. Clin. Psychopharmacol.28(1) , 27–31 (2008).
  • Ascher-Svanum H , StenslandMD, KinonBJ, TollefsonGD. Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. J. Psychopharmacol.19(Suppl. 6) , 110–117 (2005).
  • Theisen FM , GebhardtS, HaberhausenM et al. Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs. Psychiatr. Genet. 15(4) , 285–289 (2005).
  • Wehmeier PM , GebhardtS, SchmidtkeJ, RemschmidtH, HebebrandJ, TheisenFM. Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation. Psychiatry Res.133(2–3) , 273–276 (2005).
  • Zhang XY , ZhouDF, WuGY et al. BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology 33(9) , 2200–2205 (2008).
  • Lane HY , LiuYC, HuangCL et al. Risperidone-related weight gain: genetic and nongenetic predictors. J. Clin. Psychopharmacol. 26(2) , 128–134 (2006).
  • Reynolds GP , ZhangZJ, ZhangXB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet359(9323) , 2086–2087 (2002).
  • Lencz T , RobinsonDG, NapolitanoB et al. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet. Genomics20(9) , 569–572 (2010).
  • Sickert L , MullerDJ, TiwariAK et al. Association of the α 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European–Americans. Pharmacogenomics 10(7) , 1169–1176 (2009).
  • Wang YC , BaiYM, ChenJY, LinCC, LaiIC, LiouYJ. Polymorphism of the adrenergic receptor α 2A -1291C>G genetic variation and clozapine-induced weight gain. J. Neural Transm.112(11) , 1463–1468 (2005).
  • Kroeze WK , HufeisenSJ, PopadakBA et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28(3) , 519–526 (2003).
  • Nasrallah HA . Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol. Psychiatry13(1) , 27–35 (2008).
  • Nonogaki K , StrackAM, DallmanMF, TecottLH. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat. Med.4(10) , 1152–1156 (1998).
  • Tecott LH , SunLM, AkanaSF et al. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 374(6522) , 542–546 (1995).
  • Meltzer HY , MatsubaraS, LeeJC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther.251(1) , 238–246 (1989).
  • Roth BL , ShefflerDJ, KroezeWK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov.3(4) , 353–359 (2004).
  • Blum K , BravermanER, HolderJM et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J. Psychoactive Drugs 32(Suppl. i–iv) , 1–112 (2000).
  • Wang GJ , VolkowND, LoganJ et al. Brain dopamine and obesity. Lancet 357(9253) , 354–357 (2001).
  • Elman I , BorsookD, LukasSE. Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology31(10) , 2091–2120 (2006).
  • Le Foll B , GalloA, Le Strat Y, Lu L, Gorwood P. Genetics of dopamine receptors and drug addiction: a comprehensive review. Behav. Pharmacol.20(1) , 1–17 (2009).
  • Jorgensen EA , KniggeU, WarbergJ, KjaerA. Histamine and the regulation of body weight. Neuroendocrinology86(3) , 210–214 (2007).
  • Ookuma K , SakataT, FukagawaK et al. Neuronal histamine in the hypothalamus suppresses food intake in rats. Brain Res. 628(1–2) , 235–242 (1993).
  • Lecklin A , TuomistoL. The blockade of H1 receptors attenuates the suppression of feeding and diuresis induced by inhibition of histamine catabolism. Pharmacol. Biochem. Behav.59(3) , 753–758 (1998).
  • Han M , DengC, BurneTH, NewellKA, HuangXF. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Psychoneuroendocrinology33(5) , 569–580 (2008).
  • Zhang Y , ProencaR, MaffeiM, BaroneM, LeopoldL, FriedmanJM. Positional cloning of the mouse obese gene and its human homologue. Nature372(6505) , 425–432 (1994).
  • Isse N , OgawaY, TamuraN et al. Structural organization and chromosomal assignment of the human obese gene. J. Biol. Chem. 270(46) , 27728–27733 (1995).
  • Sinha MK , OpentanovaI, OhannesianJP et al. Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting. J. Clin. Invest. 98(6) , 1277–1282 (1996).
  • Licinio J , MantzorosC, Negrao Ab et al. Human leptin levels are pulsatile and inversely related to pituitary-adrenal function. Nat. Med.3(5) , 575–579 (1997).
  • Sinha MK , OhannesianJP, HeimanML et al. Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. J. Clin. Invest. 97(5) , 1344–1347 (1996).
  • Baumann H , MorellaKK, WhiteDW et al. The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc. Natl Acad. Sci. USA 93(16) , 8374–8378 (1996).
  • Thompson DB , RavussinE, BennettPH, BogardusC. Structure and sequence variation at the human leptin receptor gene in lean and obese Pima Indians. Hum. Mol. Genet.6(5) , 675–679 (1997).
  • Lee GH , ProencaR, MontezJM et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature 379(6566) , 632–635 (1996).
  • Morris DL , RuiL. Recent advances in understanding leptin signaling and leptin resistance. Am. J. Physiol. Endocrinol. Metab.297(6) , E1247–1259 (2009).
  • Zhang F , ChenY, HeimanM, DimarchiR. Leptin: structure, function and biology. Vitam. Horm.71 , 345–372 (2005).
  • Lammert A , KiessW, BottnerA, GlasowA, KratzschJ. Soluble leptin receptor represents the main leptin binding activity in human blood. Biochem. Biophys. Res. Commun.283(4) , 982–988 (2001).
  • Kloek C , HaqAK, DunnSL, LaveryHJ, BanksAS, MyersMG Jr. Regulation of Jak kinases by intracellular leptin receptor sequences. J. Biol. Chem.277(44) , 41547–41555 (2002).
  • Gong Y , Ishida-TakahashiR, VillanuevaEC, FingarDC, MunzbergH, MyersMG Jr. The long form of the leptin receptor regulates STAT5 and ribosomal protein S6 via alternate mechanisms. J. Biol. Chem.282(42) , 31019–31027 (2007).
  • Vaisse C , HalaasJL, HorvathCM, DarnellJE Jr, Stoffel M, Friedman JM. Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat. Genet.14(1) , 95–97 (1996).
  • Robertson SA , LeinningerGM, MyersMG Jr. Molecular and neural mediators of leptin action. Physiol. Behav.94(5) , 637–642 (2008).
  • Schwartz MW , WoodsSC, PorteD Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature404(6778) , 661–671 (2000).
  • Margetic S , GazzolaC, PeggGG, HillRA. Leptin: a review of its peripheral actions and interactions. Int. J. Obes. Relat. Metab. Disord.26(11) , 1407–1433 (2002).
  • Sentissi O , GrouselleD, VialaA et al. Ghrelin and leptin levels in schizophrenic patients treated with antipsychotic monotherapy. J. Clin. Psychopharmacol. 29(3) , 304–306 (2009).
  • Wang HC , YangYK, ChenPS, LeeIH, YehTL, LuRB. Increased plasma leptin in antipsychotic-naive females with schizophrenia, but not in males. Neuropsychobiology56(4) , 213–215 (2007).
  • Dieudonne MN , PecqueryR, BoumedieneA, LeneveuMC, GiudicelliY. Androgen receptors in human preadipocytes and adipocytes: regional specificities and regulation by sex steroids. Am. J. Physiol.274(6 Pt 1) , C1645–C1652 (1998).
  • Mizutani T , NishikawaY, AdachiH et al. Identification of estrogen receptor in human adipose tissue and adipocytes. J. Clin. Endocrinol. Metab. 78(4) , 950–954 (1994).
  • O‘Brien SN , WelterBH, MantzkeKA, PriceTM. Identification of progesterone receptor in human subcutaneous adipose tissue. J. Clin. Endocrinol. Metab.83(2) , 509–513 (1998).
  • Elbers JM , AsschemanH, SeidellJC, FrolichM, MeindersAE, GoorenLJ. Reversal of the sex difference in serum leptin levels upon cross-sex hormone administration in transsexuals. J. Clin. Endocrinol. Metab.82(10) , 3267–3270 (1997).
  • Machinal F , DieudonneMN, LeneveuMC, PecqueryR, GiudicelliY. In vivo and in vitro ob gene expression and leptin secretion in rat adipocytes: evidence for a regional specific regulation by sex steroid hormones. Endocrinology140(4) , 1567–1574 (1999).
  • Considine RV , SinhaMK, HeimanML et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 334(5) , 292–295 (1996).
  • Sentissi O , EpelbaumJ, OlieJP, PoirierMF. Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr. Bull.34(6) , 1189–1199 (2008).
  • Ribeiro R , VasconcelosA, CostaS et al. Overexpressing leptin genetic polymorphism (-2548 G/A) is associated with susceptibility to prostate cancer and risk of advanced disease. Prostate 59(3) , 268–274 (2004).
  • Ma D , FeitosaMF, WilkJB et al. Leptin is associated with blood pressure and hypertension in women from the national heart, lung, and blood institute family heart study. Hypertension 53(3) , 473–479 (2009).
  • Hoffstedt J , ErikssonP, Mottagui-TabarS, ArnerP. A polymorphism in the leptin promoter region (-2548 G/A) influences gene expression and adipose tissue secretion of leptin. Horm. Metab. Res.34(7) , 355–359 (2002).
  • Hager J , ClementK, FranckeS et al. A polymorphism in the 5´ untranslated region of the human ob gene is associated with low leptin levels. Int. J. Obes. Relat. Metab. Disord. 22(3) , 200–205 (1998).
  • Dahlman I , ArnerP. Obesity and polymorphisms in genes regulating human adipose tissue. Int. J. Obes. (Lond.)31(11) , 1629–1641 (2007).
  • Rosmond R . Association studies of genetic polymorphisms in central obesity: a critical review. Int. J. Obes. Relat. Metab. Disord.27(10) , 1141–1151 (2003).
  • Stratigopoulos G , LeducCA, MatsuokaN et al. Functional consequences of the human leptin receptor (LEPR) Q223R transversion. Obesity (Silver Spring) 17(1) , 126–135 (2009).
  • Furusawa T , NakaI, YamauchiT et al. The Q223R polymorphism in LEPR is associated with obesity in Pacific Islanders. Hum. Genet. 127(3) , 287–294 (2010).
  • Quinton ND , LeeAJ, RossRJ, EastellR, BlakemoreAI. A single nucleotide polymorphism (SNP) in the leptin receptor is associated with BMI, fat mass and leptin levels in postmenopausal Caucasian women. Hum. Genet.108(3) , 233–236 (2001).
  • Yiannakouris N , YannakouliaM, MelistasL, ChanJL, Klimis-ZacasD, MantzorosCS. The Q223R polymorphism of the leptin receptor gene is significantly associated with obesity and predicts a small percentage of body weight and body composition variability. J. Clin. Endocrinol. Metab.86(9) , 4434–4439 (2001).
  • Mammes O , AubertR, BetoulleD et al. LEPR gene polymorphisms: associations with overweight, fat mass and response to diet in women. Eur. J. Clin. Invest.31(5) , 398–404 (2001).
  • Heo M , LeibelRL, FontaineKR et al. A meta-analytic investigation of linkage and association of common leptin receptor (LEPR) polymorphisms with body mass index and waist circumference. Int. J. Obes. Relat. Metab. Disord. 26(5) , 640–646 (2002).
  • Paracchini V , PedottiP, TaioliE. Genetics of leptin and obesity: a HuGE review. Am. J. Epidemiol.162(2) , 101–114 (2005).
  • Sun Q , CornelisMC, KraftP et al. Genome-wide association study identifies polymorphisms in LEPR as determinants of plasma soluble leptin receptor levels. Hum. Mol. Genet. 19(9) , 1846–1855 (2010).
  • Zhang ZJ , YaoZJ, MouXD et al. Association of -2548G/A functional polymorphism in the promoter region of leptin gene with antipsychotic agent-induced weight gain. Zhonghua Yi Xue Za Zhi 83(24) , 2119–2123 (2003).
  • Ruano G , GoetheJW, CaleyC et al. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Mol. Psychiatry 12(5) , 474–482 (2007).
  • Yevtushenko OO , CooperSJ, O‘NeillR, DohertyJK, WoodsideJV, ReynoldsGP. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br. J. Psychiatry192(6) , 424–428 (2008).
  • Gregoor JG , Van Der Weide J, Mulder H et al. Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication. J. Clin. Psychopharmacol.29(1) , 21–25 (2009).
  • Gregoor JG , MulderH, CohenD et al. Combined HTR2C-LEP genotype as a determinant of obesity in patients using antipsychotic medication. J. Clin. Psychopharmacol. 30(6) , 702–705 (2010).
  • Opgen-Rhein C , BrandlEJ, MullerDJ et al. Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample. Pharmacogenomics 11(6) , 773–780 (2010).
  • Fernandez E , CarrizoE, FernandezV et al. Polymorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin. Schizophr. Res. 121(1–3) , 213–217 (2010).
  • Moons T , ClaesS, MartensGJ et al. Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs. Schizophr. Res. 125(2–3) , 187–193 (2011).
  • Ellingrod V l, Bishop JR, Moline J, Lin YC, Miller DD. Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. Psychopharmacol. Bull.40(1) , 57–62 (2007).
  • Srivastava V , DeshpandeSN, NimgaonkarVL, LererB, ThelmaB. Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes. Pharmacogenomics9(8) , 1055–1068 (2008).
  • Templeman LA , ReynoldsGP, ArranzB, SanL. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet. Genomics15(4) , 195–200 (2005).
  • Zhang XY , TanYL, ZhouDF et al. Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. J. Clin. Psychopharmacol. 27(3) , 246–251 (2007).
  • Kang SG , LeeHJ, ParkYM et al. Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(1) , 160–163 (2008).
  • Perez-Iglesias R , MataI, AmadoJA et al. Effect of FTO, SH2B1, LEP, and LEPR polymorphisms on weight gain associated with antipsychotic treatment. J. Clin. Psychopharmacol. 30(6) , 661–666 (2010).
  • Calarge CA , EllingrodVL, ZimmermanB, AcionL, SivitzWI, SchlechteJA. Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents. Psychiatr. Genet.19(6) , 320–327 (2009).
  • Gregoor JG , van der Weide J, Loovers HM, van Megen HJ, Egberts TC, Heerdink ER. Association between LEP and LEPR gene polymorphisms and dyslipidemia in patients using atypical antipsychotic medication. Psychiatr. Genet.20(6) , 311–316 (2010).
  • Kluge M , SchuldA, SchachtA et al. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology 34(1) , 118–128 (2009).
  • Vehof J , RisseladaAJ, Al Hadithy AF et al. Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication. Psychopharmacology (Berl.)216(2) , 257–265 (2011).
  • Newcomer JW . Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs19(Suppl. 1) , 1–93 (2005).
  • Thompson A , LavedanC, VolpiS. Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone. Psychiatry Res.175(3) , 271–273 (2010).
  • Tartaglia LA . The leptin receptor. J. Biol. Chem.272(10) , 6093–6 (1997).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.